Department of Cardiology, Institut Mutualiste Montsouris, Paris, France.
Hôpital Privé Jacques Cartier, Institut Cardiovasculaire Paris Sud (ICPS), Ramsay Santé, Massy, France.
EuroIntervention. 2022 May 15;18(1):50-57. doi: 10.4244/EIJ-D-21-00713.
Although the presence of a thrombus contraindicates left atrial appendage closure procedure (LAAC), a previous study reported the feasibility of the thrombus trapping procedure (TTP) technique to overcome this limitation.
This study aimed to analyse the short-term outcomes in a series of patients who underwent LAAC using the TTP (TTP-LAAC).
This retrospective series included patients who underwent TTP-LAAC between January 2018 and May 2020 in 13 European centres. Device choice, pre-interventional work-up and post-discharge antithrombotic therapy regimens were left to the discretion of the operators. The primary endpoint was the 30-day occurrence of stroke, systemic embolism or cardiovascular death.
During the study period, a total of 1,918 patients underwent LAAC. A thrombus was identified in 71 cases but completely disappeared in 24 patients before procedure. TTP-LAAC was finally performed in 53 cases (3%). Thrombi were identified ahead of the actual day of implantation in 47 patients (87%) and were mostly limited in size (50 cases with extension <50% of the LAA surface). The Amplatzer Amulet and WATCHMAN FLX occluders were implanted in 44 and 9 patients, respectively. A single deployment approach was applied in 70% and a cerebral embolic protection system was used in 9% of the patients. The overall success rate was 100%. Small pericardial effusion without tamponade was observed in 6% of the cases. Patients were discharged with 72% under antiplatelet therapy and 10% under short-term oral anticoagulation. The primary endpoint occurred in one patient.
TTP-LAAC might be used in a minority of LAAC procedures but appears to be feasible and safe in the short-term, in select cases.
尽管血栓存在是左心耳封堵术(LAAC)的禁忌症,但先前的研究报告了血栓捕获术(TTP)技术克服这一限制的可行性。
本研究旨在分析使用 TTP(TTP-LAAC)进行 LAAC 的一系列患者的短期结果。
本回顾性系列研究纳入了 2018 年 1 月至 2020 年 5 月期间在 13 个欧洲中心接受 TTP-LAAC 的患者。设备选择、术前检查和出院后抗血栓治疗方案均由操作者自行决定。主要终点是 30 天内发生的中风、全身性栓塞或心血管死亡。
在研究期间,共有 1918 名患者接受了 LAAC。71 例患者发现血栓,但在术前 24 例患者中完全消失。最终有 53 例(3%)患者进行了 TTP-LAAC。47 例患者(87%)在实际植入日之前发现血栓,且血栓大小多有限(50 例血栓延伸<左心耳表面的 50%)。Amplatzer Amulet 和 WATCHMAN FLX 封堵器分别植入 44 例和 9 例。70%的患者采用单一植入方法,9%的患者使用了脑栓塞保护系统。总体成功率为 100%。6%的患者出现少量心包积液但无填塞。72%的患者出院时接受抗血小板治疗,10%的患者短期接受口服抗凝治疗。主要终点在 1 例患者中发生。
TTP-LAAC 可能在少数 LAAC 手术中使用,但在特定情况下,短期内似乎是可行且安全的。